BMS Reports Three-Year Follow-Up Results from Exploratory Analyses of P-III Trial (CheckMate -816) for Opdivo to Treat Resectable Non-Small Cell Lung Cancer
Shots:
- The 3yr. follow-up results from exploratory analyses of the P-III trial evaluating Opdivo + CT vs CT alone as neoadjuvant treatment in patients with resectable stage IB to IIIA NSCLC
- In patients with tumor PD-L1 expression ≥1% & <1%, reduction in risk of death (63% & 29%), 3yr. OS rates (85% vs 66% & 71% vs 60%); 3yr. EFS rates (72% vs 47%) & (42% vs 39%); pCR rates (32.6% vs 2.2%) & (16.7% vs 2.6%); MPR rates (44.9% vs 5.6% & 29.5% vs 14.3%); definitive surgery rates (84% vs 74% & 81% vs 77%); complete resection (91% vs 82% & 79% vs 76%), respectively.
- At the median follow-up of 41.4mos., promising OS trends were seen in both patient populations. The safety profile was consistent across all PD-L1 subgroups & results will be presented at ESMO Congress 2023
Ref: BMS | Image: BMS
Related News:- BMS’ Opdivo (nivolumab) Receives the US FDA’s Approval as Adjuvant Treatment for Completely Resected Stage IIB or Stage IIC Melanoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
